Previous 10 | Next 10 |
Potential to Treat Parkinson’s and Other Neurodegenerative Diseases IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that its subsidiary Ta...
Blocks the RBD/ACE2 binding interaction indirectly through an alternative mechanism of action Binds to all tested variants of concern, likely because it targets a site other than the mutation prone Receptor Binding Domain/ACE2 binding interface Works synergistically ...
ImmunoPrecise Antibodies (IPA): Q3 GAAP EPS of -C$0.08.Revenue of C$4.51M (+11.9% Y/Y)Press Release For further details see: ImmunoPrecise Antibodies reports Q3 results
ImmunoPrecise and Genmab enter into a technology partnership targeting infectious disease ImmunoPrecise and Litevax advance SARS-CoV-2 vaccine candidate for further pre-clinical evaluation Commenced trading on Nasdaq stock exchange Announced positive data fro...
Can-Fite BioPharma Ltd. (CANF) +87% on out-licensing psoriasis, liver disease drug rights.SunLink Health Systems, Inc. (SSY) +55% on announcing $2 Million expansion, capital and operating improvements at Trace Regional Hospital.Annovis Bio, Inc. (ANVS) +37% as ANVS401 improves ...
The Screening Addresses Potential Approaches to Treating Emerging and Future Variants of SARS-CoV-2 Through Multi-Antibody Combination Therapy IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic an...
Management to provide corporate update on emerging SARS-CoV-2 variants of concern, (UK, S. African and Brazilian) IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery and development, today...
Stock market indices stand to finish mixed after a holiday-shortened week where Congressional hearings around GameStop (GME) dominated headlines. The Nasdaq (COMP) may eke out a small gain for the week, while the S&P 500 (SP500) is down about 0.8% at the time of this writing. Dow Industri...
ImmunoPrecise Antibodies (IPA) rises 25% premarket in reaction to the announcement of preliminary, preclinical data of TATX-03 PolyTope antibody cocktail program in SARS-CoV-2 infected hamsters.TATX-03 resulted in 100% clearance of detectable replication-competent virus fr...
Treatment of Syrian hamsters with TATX-03, a cocktail of four proprietary monoclonal antibodies directed against distinct regions of the SARS-CoV-2 spike protein, resulted in strong anti-viral effects against SARS-CoV-2 in both protective and therapeutic settings Therapeutic...
News, Short Squeeze, Breakout and More Instantly...
ImmunoPrecise Antibodies Ltd. Company Name:
IPA Stock Symbol:
NASDAQ Market:
VICTORIA, BC / ACCESSWIRE / April 22, 2024 / ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already successful LENS ai TM Platform. LENS ai , which is run by the company's subsidiary, BioStran...
VICTORIA, BC / ACCESSWIRE/ April 12, 2024 / InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability and speed challenges partnered with ImmunoPrecise Antibodies (NASDAQ:IPA) ("IPA"), an artificial intelligence-dri...
Immunoprecise Antibodies Ltd (NASDAQ:IPA), together with InterSystems, have collaborated to integrate the new vector search capability of the Int...